1. Introduction

Irinotecan is a topoisomerase I inhibitor widely used in the management of various gastrointestinal malignancies. It is a prodrug metabolized to its active form, SN-38, which exerts cytotoxic effects primarily during the S and G2 phases of the cell cycle by stabilizing DNA-topoisomerase I cleavable complexes, leading to DNA strand breaks and apoptosis.

2. Indications (Evidence-Based)

Irinotecan is a key agent in:

• Metastatic colorectal cancer (mCRC): Used as monotherapy or in combination regimens.
• Extensive small cell lung cancer (ESCC): Often combined with cisplatin.
• Metastatic cervical cancer: Under investigation, with ongoing clinical trials supporting its use.
• Metastatic pancreatic adenocarcinoma: After failure of gemcitabine-based therapy.

Note: Use in other tumor types is investigational and should be guided by clinical trial data or off-label approval per local guidelines.

3. Mechanism of Action

• Topoisomerase I Inhibition: SN-38, the active metabolite, forms covalent complexes with topoisomerase I, preventing DNA re-ligation.
• Cell Cycle Specificity: Most effective in S and G2 phases due to increased DNA replication activity.
• Metabolism: SN-38 is inactivated by hepatic UGT1A1-mediated glucuronidation (SN-38G). Genetic polymorphisms in UGT1A1 (notably *28 allele) significantly impact toxicity risk.

4. Pharmacokinetics

• Bioavailability: Oral and IV formulations have different pharmacokinetic profiles.
• Distribution: Large volume of distribution (~400 L/m²), indicating extensive tissue penetration.
• Metabolism: Hepatic (CYP3A4/2C8/2C19), with major inactivation by UGT1A1.
• Excretion: Primarily via biliary excretion as SN-38G.

5. Dosing Regimens (Current Guidelines)

A. Monotherapy in mCRC:

• Weekly regimen: 125 mg/m² IV over 90 min on days 1, 8, 15, and 22 of a 6-week cycle; may escalate to 150 mg/m² if tolerated.
• Every-three-weeks regimen: 350 mg/m² IV over 90 min (or 300 mg/m² for dose reductions).
• Dose adjustments:
  • -1 ADI: 100 mg/m²
  • -2 ADI: 75 mg/m²
  • Further reductions in increments of 25–50 mg/m² as needed.
• Concomitant use: Leucovorin and fluorouracil (5-FU) are often administered to enhance efficacy.

B. Combination regimens:

• Regimen 1: 125 mg/m² IV + leucovorin + bolus/infusion of 5-FU, every 3 weeks.
• Regimen 2: 180 mg/m² IV over 1.5 hours (every 3 weeks), with leucovorin and 5-FU as above.

Always verify product labels for batch-specific dosing instructions.

6. Dose Modifications & Special Populations

• UGT1A1 Genotype: Patients homozygous for UGT1A1*28 (poor metabolizers) have increased risk of severe neutropenia and diarrhea; consider dose reduction or alternative therapy.
• Performance Status: For patients with poor performance status (ECOG 2+), reduce initial dose by at least one level.
• Renal/Hepatic Impairment: Use caution in hepatic dysfunction; avoid in decompensated liver disease.

7. Administration

• Route: IV only, administered over 45–90 minutes depending on regimen.
• Stability: Solutions are stable at room temperature for up to 24 hours (5% Dextrose USP); refrigeration (2–8°C) extends stability to 48 hours (avoid freezing).
• Premedication: Consider anticholinergics (atropine 0.25–1 mg IV/SC) for patients with history of cholinergic symptoms or high risk of diarrhea.
• Infusion Rate: Slower infusion rates reduce acute toxicity, especially diarrhea.

8. Adverse Effects & Management

Most common (>30%):

• Diarrhea: Early (within 24 hours) and late (after 24 hours; peaks ~11 days post-dose).
  • Management: Prophylactic loperamide, hydration, dose interruption if severe.
• Nausea/Vomiting: Managed with antiemetics (5-HT3 antagonists, dexamethasone).
• Myelosuppression: Neutropenia and anemia are common; monitor CBC regularly.
• Other: Mucositis, alopecia, fatigue.

Late-onset diarrhea: Requires prompt intervention to prevent dehydration and hospitalization.

9. Drug Interactions

• Increased Toxicity:
  • Laxatives: Risk of severe diarrhea; avoid unless absolutely necessary.
  • CYP3A4/2C8/2C19 inhibitors (e.g., ketoconazole, clarithromycin): May increase irinotecan levels.
  • St. John’s Wort: Induces CYP3A4, reduces efficacy.
  • Dextromethorphan, prochlorperazine: Risk of serotonin syndrome.
• Decreased Efficacy:
  • Enzyme inducers (e.g., rifampin): May reduce plasma levels.

Always review concomitant medications for interactions.

10. Contraindications & Precautions

• Absolute contraindications: Hypersensitivity, pre-existing severe liver disease, peritoneal metastases of gastric cancer.
• Relative contraindications: Severe hepatic impairment, history of severe diarrhea or neutropenia.

11. Pregnancy and Lactation

• Pregnancy: Teratogenic; avoid in pregnancy (risk to fetus).
• Post-treatment: Avoid conception for at least 6 months after last dose.
• Lactation: Excreted in breast milk; avoid breastfeeding during therapy and for several months post-discontinuation.

12. Storage & Handling

• Stability: Protect from light, refrigerate (2–8°C) if diluted; use within 24 hours at room temp.
• Preparation: Use clean technique; avoid freezing CAMPTOSAR/irinotecan admixtures to prevent precipitation.

13. Clinical Monitoring Recommendations

• Baseline: CBC, LFTs, renal function, UGT1A1 genotype (if available).
• During therapy: Monitor for neutropenia, anemia, thrombocytopenia; assess bowel function closely.
• Diarrhea management: Early intervention is crucial to prevent complications.

14. Summary for Pharmacists

Irinotecan is a potent chemotherapeutic agent with significant toxicity risks, especially gastrointestinal and hematologic. Pharmacists play a vital role in:

• Ensuring correct dosing based on genotype (UGT1A1*28), performance status, and prior toxicity.
• Educating patients about diarrhea prevention and management.
• Monitoring for drug interactions and adverse effects.
• Advising on safe storage, handling, and administration protocols.

References:

• NCCN Guidelines®: Colon & Rectal Cancers (2024)
• ESMO Clinical Practice Guidelines (2023)
• ASCO Chemotherapy Guidelines (2022)
• FDA Labeling and Product Monographs

In summary:
Irinotecan is a cornerstone in oncology, but its use requires vigilant monitoring and patient education to optimize outcomes and minimize harm. Pharmacists should be familiar with current guidelines, genetic considerations, and practical management strategies for this complex medication.